BOCH
LENZ

Blue Owl Capital Holdings’s LENZ Therapeutics LENZ Stock Holding History

Blue Owl Capital Holdings’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.64M Buy
506,722
+356,722
+238% +$5.01M 1.25% 21
2025
Q4 		$2.4M Buy
+150,000
New +$4.37M 0.74% 33

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Blue Owl Capital Holdings's LENZ Position: Q1 2026 in Review

Blue Owl Capital Holdings increased its LENZ Therapeutics (LENZ) stake by 238% in Q1 2026, buying an estimated $5.01M and bringing the position to 506,722 shares worth $4.64M. The position accounts for 1.25% of the portfolio, ranked #21.

Blue Owl Capital Holdings first reported a position in LENZ in Q4 2025 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Blue Owl Capital Holdings held 506,722 shares of LENZ Therapeutics worth $4.64M as of Q1 2026.
  • Blue Owl Capital Holdings bought 356,722 LENZ Therapeutics shares in Q1 2026, an estimated $5.01M.
  • LENZ Therapeutics made up 1.25% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #21 holding.
  • Blue Owl Capital Holdings first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.